TrialClinical epigenetics2022

Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.

Chaoyuan Kuang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.